Le Lézard
Classified in: Oil industry, Science and technology

Goldwind Announces GW4S Smart Wind Turbine


BEIJING, Nov. 14, 2017 /PRNewswire/ -- Xinjiang Goldwind Science & Technology Co., Ltd, (Goldwind) (SZSE: 002202) (HK: 2208), announced today the release of its GW4S smart wind turbine. The product maintains Goldwind's Permanent Magnet Direct Drive (PMDD) turbine technology and is a direct evolution of the existing 3S platform ? a turbine series that has industry-leading availability and performance.

Goldwind GW4S Smart Wind Turbine

Goldwind's 4S Permanent Magnet Direct-Drive (PMDD) wind turbine capitalizes on the scalability and supply chain of the 3S platform to bring turbines with a rated power range between 4.0 and 4.2MW. The latest Goldwind turbine for international markets is designed for wind class IIA and features rotor diameters up to 136 meters.

"A prototype of the GW4S will be installed during the second quarter of 2018 in China. The turbine will be ready for international commercial deployment in the first quarter of 2019 and target markets include North America, Australia, South America and Turkey," said Tony Pan, CEO of Goldwind International.

About Goldwind
Xinjiang Goldwind Science & Technology Co., Ltd is a world leading wind turbine technology and energy solutions provider (SZSE: 002202) (HK: 2208). With more than 40 GW of capacity worldwide, Goldwind's revolutionary Permanent Magnet Direct Drive (PMDD) technology is shaping a new standard in wind energy. Goldwind offers a full suite of innovative renewable energy solutions, including equipment manufacturing and sales, service, and investment. To learn more, visit www.goldwindinternational.com

U.S. Media Contact:
Lauren La Marche
Goldwind Americas
Senior Manager, Corporate Communications
D: +1 312-948-8049
M: +1 602-717-3223
E: [email protected]

Australia Media Contact:
Kristina Sokolovska
Goldwind Australia
M: 61 436 662 319
E: [email protected]

Other International Markets Media Contact:
Sofia Zheng
Goldwind International
Marketing Manager
D: +86 67511888-2163
M: +18518098864
E: [email protected]

Goldwind Beijing Media Contact:
Jessie Wang
Goldwind Headquarters
Manager, Public Relations
D: +86 10 6751-1888-1021
E: [email protected]

 

GOLDWIND Logo

SOURCE Goldwind


These press releases may also interest you

at 21:30
Rubrik Announces Pricing of Upsized Initial Public Offering
Rubrik, Inc. today announced the pricing of its upsized initial public offering of 23,500,000 shares of its Class A common stock at a public offering price of $32.00 per share. In addition, Rubrik has granted the underwriters a 30-day option to...

at 21:27
Labcorp Announces Winning Bid for Select Assets of Invitae
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed,...

at 21:26
Flash News: OKX DeFi Launches 'zkSwap Bonus Event' Offering Users the Opportunity to Earn a Bonus APR
OKX, a leading Web3 technology company, has issued updates for April 24, 2024. OKX DeFi Launches 'zkSwap Bonus Event' Offering Users...

at 21:19
Invitae Enters into Agreement with Labcorp for Sale of Business
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...

at 21:05
TransAlta Declares Dividends
The Board of Directors of TransAlta Corporation declared a quarterly dividend of $0.06 per common share payable on July 1, 2024 to shareholders of record at the close of business on June 1, 2024. The Board of Directors also declared the following...

at 21:02
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...

More news about Science and technology...


News published on and distributed by: